Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press1698010.36691/RJA16980Case reportsКлинические случаиResearch ArticleTransient adverse events associated with the use of dupilumab in a child with severe atopic dermatitisТранзиторные нежелательные явления, ассоциированные с использованием дупилумаба у ребенка с тяжелым течением атопического дерматитаhttps://orcid.org/0000-0003-4295-725X2698-6740VarlamovEvgeniy E.ВарламовЕвгений Евгеньевич
Russian Federation

MD, Cand. Sci. (Medicine)

канд. мед. наук

varlamov80@mail.ruhttps://orcid.org/0000-0001-5039-84739722-7961PampuraAleksandr N.ПампураАлександр Николаевич
Russian Federation

MD, Dr. Sci. (Medicine), Professor

д-р мед. наук, профессор

apampura1@mail.ruThe Russian National Research Medical University named after N.I. PirogovРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаMorozov Children’s City Clinical HospitalМорозовская детская городская клиническая больницаRussian Medical Academy of Continuing Professional EducationРоссийская медицинская академия непрерывного профессионального образования21052025101020252233263341711202415052025Copyright ©; 2025, ABV-pressCopyright ©; 2025, ИД "АБВ-пресс"2025ABV-pressИД "АБВ-пресс"https://rusalljournal.ru/raj/article/view/16980

Atopic dermatitis is a multifactorial inflammatory skin disease with genetic predisposition characterized by itching, chronic relapsing course, age-dependent localization and morphology of the lesions. In a situation where external therapy for moderate to severe atopic dermatitis does not have sufficient effect, patients are prescribed systemic therapy. Currently, dupilumab is the first line systemic therapy option for the treatment of moderate to severe atopic dermatitis. Along with its high effectiveness, a number of side effects have been described.

This article describes a clinical case of a patient with severe atopic dermatitis and food allergy, who started therapy with dupilumab. During the treatment, the patient experienced several subsequent adverse effects: conjunctivitis, herpes infection, eosinophilia.

Атопический дерматит — мультифакторное генетически детерминированное воспалительное заболевание кожи, характеризующееся зудом, хроническим рецидивирующим течением, возрастными особенностями локализации и морфологии очагов поражения. В случае, когда наружная терапия при среднетяжелом и тяжелом атопическом дерматите не оказывает достаточного эффекта, пациентам назначают системную терапию. Одним из лекарственных средств для системной терапии атопического дерматита является генно-инженерный биологический препарат дупилумаб. Наряду с его высокой эффективностью описан ряд побочных эффектов, которые могут возникать на фоне лечения.

В статье представлено описание клинического случая пациента с тяжелым атопическим дерматитом и поливалентной пищевой аллергией, которому инициирована терапия дупилумабом. На фоне проводимого лечения у пациента наблюдалось последовательное развитие нескольких нежелательных эффектов — конъюнктивита, герпетической инфекции, эозинофилии.

childrenatopic dermatitisdupilumabclinical caseдетиатопический дерматитдупилумабклинический случайАтопический дерматит. Клинические рекомендации. Москва. 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/265_3Wollenberg A, Werfel T, Ring J, et al. Atopic dermatitis in children and adults — diagnosis and treatment. Dtsch Arztebl Int. 2023;120(13):224–234. doi: 10.3238/arztebl.m2023.0011 EDN: VAXHMUNoda S, Kreuger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324–336. doi: 10.1016/j.jaci.2014.11.015 EDN: UOJYCPBrunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–S76. doi: 10.1016/j.jaci.2017.01.011 EDN: ZABDXHGandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443 EDN: YVGHFAHamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–1300. doi: 10.1016/j.jaci.2014.10.013Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28–S36. doi: 10.1016/j.jaad.2017.12.022 EDN: BSWBOESeegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467–474. doi: 10.1080/17512433.2018.1449642 EDN: XCSHDMBeck LA, Bissonnette R, Deleuran M, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805–812. doi: 10.1001/jamadermatol.2024.1536Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393–408. doi: 10.1007/s40257-022-00685-0 EDN: ADDOGOKulthanan K, Tuchinda P, Nitiyarom R, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pac J Allergy Immunol. 2021;39(3):145–155. doi: 10.12932/AP-010221-1050 EDN: LERDSOChu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274–312. doi: 10.1016/j.anai.2023.11.009 EDN: BHXLKERyser FS, Yalamanoglu A, Valaperti A, et al. Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. Allergy. 2023;78(10):2712–2723. doi: 10.1111/all.15844 EDN: YIZSNXWechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. Allergy Clin Immunol Pract. 2022;10(10):2695–2709. doi: 10.1016/j.jaip.2022.05.019 EDN: WTAUNMMarcant P, Balayé P, Merhi R, et al. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2021;35(6):e394–e396. doi: 10.1111/jdv.17177 EDN: KAHQSAAhn J, Bae JY, Seo SJ. A retrospective case series hypereosinophilia during dupilumab treatment: hypereosinophilia could be a pharmacogenetic biomarker of dupilumab. Dermatol Ther. 2020;33(6):e13847. doi: 10.1111/dth.13847 EDN: GOPJBKLommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia. Allergy. 2021;76(9):2920–2923. doi: 10.1111/all.14964 EDN: BCSAGGDescamps V, Deschamps L, El Khalifa J, et al. Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Respir Med Res. 2021;79:100821. doi: 10.1016/j.resmer.2021.100821 EDN: EFFNWUKurihara M, Masaki K, Matsuyama E, et al. How can dupilumab cause eosinophilic pneumonia? Biomolecules. 2022;12(12):1743. doi: 10.3390/biom12121743 EDN: XIYBCRNeagu N, Dianzani C, Avallone G, et al. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(6):820–835. doi: 10.1111/jdv.17981 EDN: BRZCYBAkinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473. doi: 10.1111/bjd.17869 EDN: RGJHSEOu Z, Chen C, Chen A, et al. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303–310. doi: 10.1016/j.intimp.2017.11.031 EDN: KIDKHSJun I, Kim BR, Park SY, et al. Interleukin-4 stimulates lipogenesis in meibocytes by activating the STAT6/PPARg signaling pathway. Ocul Surf. 2020;18(4):575–582. doi: 10.1016/j.jtos.2020.04.015 EDN: JRQAUTGarcía-Posadas L, Hodges RR, Diebold Y, Dartt DA. Context-dependent regulation of conjunctival goblet cell function by allergic mediators. Sci Rep. 2018;8(1):12162. doi: 10.1038/s41598-018-30002-x EDN: VRBQKZWang Y, Jorizzo JL. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration. J Am Acad Dermatol. 2021;84(4):1010–1014. doi: 10.1016/j.jaad.2020.11.042 EDN: GSNBCKEichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456. doi: 10.1007/s40257-019-00445-7 EDN: XCNSIKPaller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464–475. doi: 10.1111/jdv.16928 EDN: ICFUKOAgache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines — dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: 10.1111/all.14690 EDN: ZMFKMHRao M, Grove D, Haggstrom A. A rare presentation of herpes simplex virus encephalitis occurring in a pediatric patient on dupilumab for atopic dermatitis. Pediatr Dermatol. 2022;39(2):288–290. doi: 10.1111/pde.14970 EDN: EYBHDZNarla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86(3):628–636. doi: 10.1016/j.jaad.2021.06.017 EDN: OYXWHZNarantsatsral D, Junko T, Hideyuki I, et al. Painless thyroiditis in a dupilumab-treated patient. Endocrinol Diabetes Metab Case Rep. 2020;2020:20–0030. doi: 10.1530/EDM-20-0030 EDN: ECRHPM